Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Tobacco Use Disorder 1Stomach Neoplasms 1Smoking Cessation 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Noncommunicable Diseases 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma 1Lung Neoplasms 1Ischemic Stroke 1Chronic Disease 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1Behavior 1Abdomen, Acute 1

Interventions

pembrolizumab 10Cisplatin 9Cetuximab 9Paclitaxel 5Radiotherapy 4Nivolumab 4Fluorouracil 4zalutumumab 3Docetaxel 3Taxes 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Gefitinib 2Cyclophosphamide 2Carboplatin 2temsirolimus 1sintilimab 1poly ICLC 1osimertinib 1fludarabine phosphate 1fludarabine 1enzalutamide 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1abemaciclib 1Vorinostat 1Sorafenib 1Risk Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡